CYNATA THERAPEUTICS LIMITED — Investor Relations & Filings

Cynata Therapeutics Limited specializes in the development of regenerative medicine therapies through its proprietary Cymerus platform technology. This platform leverages induced pluripotent stem cells (iPSCs) to manufacture mesenchymal stem cells (MSCs) at scale, providing a consistent source of therapeutic cells without reliance on multiple donors. The company's clinical focus includes the treatment of graft-versus-host disease (GvHD), osteoarthritis, and diabetic foot ulcers. By utilizing a single master cell bank, the Cymerus process enables the production of off-the-shelf MSC products designed to treat various inflammatory and autoimmune disorders. The lead candidate, CYP-001, has undergone clinical evaluation for steroid-resistant acute GvHD, demonstrating the platform's potential to address significant unmet medical needs through standardized cellular therapeutics.